Effects of Inhaled β 2 ‐ AR Agonists in Athletes According to the WADA 2025 List: New Insights From a Systematic Review and Meta‐Analysis
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
ABSTRACT This systematic review and meta‐analysis (CRD420251006746) investigated the impact of inhaled β 2 ‐adrenoceptor (AR) agonists (IBA) with exemption according to the World Anti‐Doping Agency (WADA) 2025 list on athletic performance, respiratory, and cardiovascular outcomes. A key subgroup analysis focused on IBA administered within WADA 2025 permitted dose intervals. Findings indicate that IBA significantly improved sprint time by 0.30 s (95% CI 0.52–0.07) overall, and by 0.27 s (95% CI 0.50–0.05) in healthy subjects, with long‐acting β 2 ‐AR agonists yielding a 0.49 s (95% CI 0.81–0.17) improvement. These sprint time enhancements persisted even at WADA‐permitted doses. Blood lactate levels significantly increased by 0.67 mmol/L (95% CI 0.19–1.14) overall and by 0.65 mmol/L (95% CI 0.17–1.14) in healthy subjects, though this effect was not significant at WADA‐permitted doses. IBA significantly improved forced expiratory volume in 1 s by 0.19 L (95% CI 0.14–0.23) and forced expiratory flow between 25% and 75% by 0.40 L/s (95% CI 0.24–0.56), with lung function improvements confirmed at WADA‐permitted doses. Heart rate significantly increased by 1.40 bpm (95% CI 0.32–2.48). IBA did not influence aerobic performance. When administered within WADA 2025 permitted doses, IBA can provide small but relevant gains in anaerobic performance in healthy individuals, while simultaneously offering therapeutic bronchodilation for athletes with asthma or exercise‐induced bronchoconstriction. Dose restrictions are critical to minimize the risk of performance enhancement that exceeds therapeutic intent and to mitigate adverse effects. Further research is pivotal to ensure that anti‐doping policies align with health standards and ethical considerations for all athletes.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Effects of Inhaled β <sub>2</sub> ‐ <scp>AR</scp> Agonists in Athletes According to the <scp>WADA</scp> 2025 List: New Insights From a Systematic Review and Meta‐Analysis
- Date Crossref
- 31/12/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.